Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nuvalent, Inc. (NUVL : NSDQ)

• Company Description    Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass. Number of Employees: 62

• Price / Volume Information    Yesterday's Closing Price: $42.50 Daily Weekly Monthly 20 Day Moving Average: 230,072 shares Shares Outstanding: 56.82 (millions) Market Capitalization: $2,414.88 (millions) Beta: 1.44 52 Week High: $44.61 52 Week Low: $8.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 9.82% 5.66% 12 Week 54.71% 43.62% Year To Date 42.71% 29.81%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One Broadway 14thFloor - Cambridge,MA 02142 USA ph: 857-357-7000 fax: - chelcie@thrustsc.com http://www.nuvalent.com

• General Corporate Information    Officers James R. Porter - Chief Executive Officer; President and Director Alexandra Balcom - Chief Financial Officer and Treasurer Emily Drabant Conley - Director Andrew A. F. Hack - Director Michael Meyers - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 670703107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/09/23 Share - Related Items Shares Outstanding: 56.82 Most Recent Split Date: (:1) Beta: 1.44 Market Capitalization: $2,414.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.22 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.44 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -22.22% vs. Previous Quarter: 10.20% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - -25.63 12/31/22 - -26.81 09/30/22 - -27.99 ROA 03/31/23 - -24.59 12/31/22 - -25.74 09/30/22 - -26.96 Current Ratio 03/31/23 - 26.81 12/31/22 - 24.54 09/30/22 - 18.90 Quick Ratio 03/31/23 - 26.81 12/31/22 - 24.54 09/30/22 - 18.90 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - 7.81 12/31/22 - 9.59 09/30/22 - 4.88 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©